Close Menu

NEW YORK (GenomeWeb) – Natera and Swiss biotech Amal Therapeutics plan to partner on a clinical trial to test Natera's bespoke circulating tumor DNA assay, Signatera, to assess treatment response in late-stage colorectal cancer patients.

The prospective clinical trial will assess Amal's cancer vaccine, ATP128, in combination with a PD-1 inhibitor in patients with stage IV colorectal cancer. Study investigators will use Signatera to measure patients' treatment response.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Dec
10
Sponsored by
Congenica II

This webinar will discuss the use of next-generation sequencing and an optimized variant interpretation workflow to increase diagnostic yield in complex clinical cases.